Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04708821 · ClinicalTrials.gov registry record · Phase 4
DEXTENZA Therapy for Treatment of Allergic Conjunctivitis
A Phase 4 study of Bilateral Conjunctivitis (Disorder), sponsored by Clinical Research Center of Florida.
- Completed
- Registry status
- Phase 4
- Development phase
- 31
- Enrollment target
- 1
- Study location
NCT04708821 is a Phase 4 study of Bilateral Conjunctivitis (Disorder) that has completed, run by Clinical Research Center of Florida. The registered enrollment target is 31 participants. The trial reports 1 study location across 1 state.
The verdict
NCT04708821, a Phase 4 study of Bilateral Conjunctivitis (Disorder), has completed, sponsored by Clinical Research Center of Florida.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 31 participants
- Enrollment target
- 1
- Study location
Study Summary
This prospective, open-label, single-center, randomized, investigator-sponsored clinical study seeks to compare patient-reported and clinical outcomes with DEXTENZA versus topical steroid or antihistamine treatment in patients with allergic conjunctivitis
Conditions Studied
Interventions
- DRUG olopatadine hydrochloride ophthalmic solution 0.7%
- DRUG Dexamethasone ophthalmic insert 0.4Mg
- DRUG 0.2% loteprednol etabonate ophthalmic suspension
Study Locations (1)
Florida
- Clinical Research Center of Florida - Pompano Beach
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2021-04-30 |
| Est. Completion | 2021-09-02 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04708821
The ClinicalTrials.gov registry entry for NCT04708821 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Clinical Research Center of Florida, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Bilateral Conjunctivitis (Disorder) appearing as the primary indexed condition, and to 3 interventions - of which olopatadine hydrochloride ophthalmic solution 0.7% is the first listed.
NCT04708821 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT04708821 about?
NCT04708821 is a clinical study titled "DEXTENZA Therapy for Treatment of Allergic Conjunctivitis". This prospective, open-label, single-center, randomized, investigator-sponsored clinical study seeks to compare patient-reported and clinical outcomes with DEXTENZA versus topical steroid or antihistamine treatment in patients with allergic conjunctivitis
What is the current status of trial NCT04708821?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 31 participants. The study started on 2021-04-30. Estimated completion is 2021-09-02.
What conditions does trial NCT04708821 study?
This clinical trial studies the following conditions: Bilateral Conjunctivitis (Disorder).
What interventions are being tested in trial NCT04708821?
The interventions under investigation include: olopatadine hydrochloride ophthalmic solution 0.7% (DRUG), Dexamethasone ophthalmic insert 0.4Mg (DRUG), 0.2% loteprednol etabonate ophthalmic suspension (DRUG).
Who is sponsoring clinical trial NCT04708821?
This trial is sponsored by Clinical Research Center of Florida, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04708821 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.